This site is intended for U.S. residents only. For Novartis Worldwide, Click here

Mailing List


	Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only.

Study Description

Screening

Study Centers

Contact/Consent

Diabetes

In diabetes, there are elevated blood sugar levels due to absolute or relative insufficiencies of insulin. There are two types of diabetes: type 1 (previously called insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes) and type 2 (previously called non-insulin-dependent diabetes mellitus (NIDDM) or maturity-onset diabetes). There are signs that type 2 diabetes is being diagnosed more often in adolescents and young adults, due to sedentary lifestyles and 'fast-food' eating habits. Most type 2 diabetics produce variable, even normal, amounts of insulin, but have abnormalities in liver and muscle cells that resist its action.

Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial.

How to use this system:

The purpose of this system is to help connect interested study participants with clinical research centers. The following is a brief outline explaining the main steps involved in using this system. Please note that every step in this process is optional.

1. Select a clinical trial that you feel best suits your (or the      participant's) health condition.
2. Answer the screening questions to see if you (or the      participant) meet the preliminary qualifications for the study.      The answers to these questions are not retained by this      system.
3. Select a study center to contact for additional information      about the clinical trial.
4. Set up an account and agree to the terms of use for this      system.
5. Submit your information to the study center you selected.
6. The study center may contact you and may ask more      questions about your (or the participant's) eligibility for the      study. The study center may invite you (and the participant if      applicable) to travel to the study center for additional screening      tests. Novartis cannot guarantee that you will be contacted by      the study center.
7. If you are eligible to participate in the study, then you will be      required to sign an informed consent before enrolling in the      study. An informed consent is provided to you to help you      understand the clinical trial, the nature of the medical treatment      (if any), procedures and known risks involved, before you agree      to participate in the study.

For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy.

Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.

ALTITUDE Diabetes Study CSPP100E2337

The purpose of this clinical research study is to determine if the investigational drug aliskiren delays or prevents the occurrence of heart and/or kidney complications in participants with type 2 diabetes who are taking medications for heart and/or kidney problems. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3
Participation Duration: Depending on when participants join this study, their participation may last for two to four years with up to 23 scheduled visits.
Protocol Number: CSPP100E2337

Diabetes Study CLAF237A 23138

The purpose of this study is to determine if an investigational drug is safe to lower blood sugar in patients with diabetic nephropathy. Diabetic Nephropathy is a term used to describe kidney disease that occurs as a result of diabetes. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3b
Participation Duration: The study will up to take up to 26 weeks (6 months 2 weeks). The participant will be required to visit the study center at least 9 times. After completing the study, participants may be asked to join a study extension.
Protocol Number: CLAF237A 23138

	Site Map \| Contact Us \| Clinical Trial Search \| Mailing List \| Clinical Trial FAQs
	Participation FAQs \| Clinical Trials Glossary \| About Informed Consent
	Novartis Medical and Clinical Research

Clinical Trial Search

Diabetes